Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
Authors:
Open Access
- 19 December 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 58 (5) , 849-858
Abstract
Objective: Safety and efficacy of mAbs blocking the IL-6 receptor have been established in RA. This is the first analysis examining safety and tolerability of sarilumab and tocilizumab administered as single or multiple doses in patients with RA within the same study. Methods: In ASCERTAIN, patients were randomized 1: 1: 2 to 24 weeks’ double-blind sarilumab 150 or 200 mg every 2 weeks s.c. or tocilizumab 4 mg/kg every 4 weeks i.v., increased to 8 mg/kg if clinically indicated. In Study 1309, patients were randomized 1: 1: 1: 1 to single-dose open-label sarilumab 150 or 200 mg s.c. or tocilizumab 4 or 8 mg/kg i.v. Results: In ASCERTAIN, incidence of treatment-emergent adverse events was similar between sarilumab and tocilizumab. The most common treatment-emergent adverse events were the following: sarilumab: neutropenia [6 patients (12.2%) in the 150 mg group and 8 (15.7%) in the 200 mg group], nasopharyngitis [6 (12.2%) and 3 (5.9%)], and injection-site erythema [4 (8.2%) and 4 (7.8%)]; tocilizumab: accidental overdose [9 (8.8%)], upper respiratory tract infection [7 (6.9%)] and nausea [7 (6.9%)]. Laboratory changes in both studies included decreased neutrophils and platelets and increased transaminases and lipids. In Study 1309, incidence of absolute neutrophil count <1.0 giga/l was similar between sarilumab and tocilizumab, and occurred more frequently in the higher dose groups. No association between decrease in absolute neutrophil count and increased incidence of infection was observed in either study. Conclusion: No clinically meaningful differences in treatment-emergent adverse events were observed between sarilumab and tocilizumab. Laboratory changes with sarilumab were within the same range as those with tocilizumab. Trial registration numbers: ASCERTAIN (NCT01768572); Study 1309 (NCT02097524).Keywords
Funding Information
- Sanofi Genzyme
- Regeneron Pharmaceuticals
- Abbott Laboratories
- Eli Lilly
- Sanofi
- Regeneron Pharmaceuticals
- Inc.
This publication has 12 references indexed in Scilit:
- Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III StudyArthritis & Rheumatology, 2015
- Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapyAnnals of the Rheumatic Diseases, 2014
- Interleukin 6 and Rheumatoid ArthritisBioMed Research International, 2014
- Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritisRheumatology, 2012
- Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approachJournal of Pharmacokinetics and Pharmacodynamics, 2011
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeAnnals of the Rheumatic Diseases, 2010
- The role of Interleukin 6 in the pathophysiology of rheumatoid arthritisTherapeutic Advances in Musculoskeletal Disease, 2010
- Neutrophil kinetics in health and diseaseTrends in Immunology, 2010
- Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy studyArthritis & Rheumatism, 2008
- The american college of rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritisArthritis & Rheumatism, 1992